Back to Search
Start Over
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.
- Source :
- Carcinogenesis; Oct2007, Vol. 28 Issue 10, p2139-2139, 1p
- Publication Year :
- 2007
-
Abstract
- Tamoxifen is a selective estrogen receptor modulator that is used to treat and to prevent breast cancer; however, its use is associated with an increased risk of endometrial cancer. Tamoxifen is metabolized by various cytochrome P450 (CYP) enzymes, but predominantly by CYP3A4. In this study, we examined whether a genetic variant of the CYP3A4 gene, CYP3A4*1B, influences endometrial cancer risk—alone and when associated with tamoxifen exposure. We conducted a case–control study on 566 endometrial cancer cases and 964 ethnically matched controls. The variant CYP3A4 allele was present in 6% of the controls and 9% of the endometrial cancer patients (OR = 1.6, 95% CI = 1.1–2.3, P = 0.02). The allele was more common in women with endometrial cancer who had been treated with tamoxifen for breast cancer (16%). Women who carried the CYP3A4*1B allele had ∼3-fold increase in the risk of developing endometrial cancer following tamoxifen treatment, compared with women who did not take tamoxifen (P = 0.004). These findings suggest that a subgroup of breast cancer patients who carry the CYP3A4*1B allele and take tamoxifen may be at increased risk of developing endometrial cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- TAMOXIFEN
SELECTIVE estrogen receptor modulators
CYTOCHROMES
ENZYMES
Subjects
Details
- Language :
- English
- ISSN :
- 01433334
- Volume :
- 28
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Carcinogenesis
- Publication Type :
- Academic Journal
- Accession number :
- 27011587
- Full Text :
- https://doi.org/10.1093/carcin/bgm087